Get the Stockscreener App
7.60
1.68%
-0.13
After Hours:
7.64
0.04
+0.53%
Immucell Corp stock is traded at $7.60, with a volume of 30,967.
It is down -1.68% in the last 24 hours and up +19.31% over the past month.
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
See More
Previous Close:
$7.73
Open:
$7.7
24h Volume:
30,967
Relative Volume:
1.67
Market Cap:
$68.76M
Revenue:
$27.64M
Net Income/Loss:
$-1.04M
P/E Ratio:
-66.84
EPS:
-0.1137
Net Cash Flow:
$1.22M
1W Performance:
+19.12%
1M Performance:
+19.31%
6M Performance:
+14.63%
1Y Performance:
+41.00%
1-Day Range:
$7.50
$7.805
1-Week Range:
$6.75
$7.82
52-Week Range:
$4.52
$7.82
Immucell Corp Stock (ICCC) Company Profile
Name
Immucell Corp
Sector
Industry
Phone
(207) 878-2770
Address
56 EVERGREEN DR, PORTLAND, ME
Compare ICCC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCC
Immucell Corp
|
7.60 | 69.93M | 27.64M | -1.04M | 1.22M | -0.1137 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Immucell Corp Stock (ICCC) Latest News
650K-share equity plan and officer exculpation up for vote — ImmuCell (NASDAQ: ICCC) - Stock Titan
ImmuCell (ICCC) VP Brockmann granted 5,000 incentive stock options - Stock Titan
ImmuCell (ICCC) director receives grant of 10,000 stock options - Stock Titan
ImmuCell (ICCC) director awarded 10,000 stock options at $5.49 strike - Stock Titan
ImmuCell (ICCC) director awarded 10,000 options at $5.49 exercise price - Stock Titan
ImmuCell (ICCC) director Steven Rosgen granted 10,000 stock options at $5.49 - Stock Titan
ImmuCell (ICCC) director receives 10,000 non-qualified stock options at $5.49 - Stock Titan
ImmuCell (ICCC) adds industry veterans to a smaller, more independent board - Stock Titan
ImmuCell appoints two directors, expands to 7-member board - Investing.com
ImmuCell appoints two directors, expands to 7-member board By Investing.com - Investing.com South Africa
Two animal health veterans join ImmuCell as board shrinks to 7 - Stock Titan
ICCC SEC FilingsImmucell 10-K, 10-Q, 8-K Forms - Stock Titan
ImmuCell Corporation Reports 35.7% Increase in Domestic Sales for 2026 – SEC 8-K Filing Highlights - Minichart
ImmuCell reports 28% sales increase in first quarter - Investing.com
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results - The Manila Times
ImmuCell (ICCC) Q1 2026 sales jump 28.4% on Tri-Shield strength - Stock Titan
Immucell Corporation Announces Preliminary, Unaudited Sales Results for the Firs Quarter of 2026 - marketscreener.com
Published on: 2026-04-08 23:34:29 - baoquankhu1.vn
IMMUCELL (ICCC) director Kathy V. Turner files initial insider Form 3 - Stock Titan
ICCC PE Ratio & Valuation, Is ICCC Overvalued - Intellectia AI
Volume Report: Will ImmuCell Corporation be affected by tariffs2026 Market Trends & Low Risk Entry Point Guides - baoquankhu1.vn
ImmuCell (NASDAQ: ICCC) boosts 2025 margins, shifts from Re‑Tain to core First Defense calf-health line - Stock Titan
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving AverageHere's Why - MarketBeat
ImmuCell (NASDAQ:ICCC) Stock Crosses Above 200 Day Moving Average – Here’s Why - Defense World
ICCC Technical Analysis | Trend, Signals & Chart Patterns | IMMUCELL CORP (NASDAQ:ICCC) - chartmill.com
ImmuCell (ICCC) director exercises 25,000 options and ends with 205,700 shares - Stock Titan
ImmuCell (ICCC) CEO granted 109,500 stock options with strict profit hurdle - Stock Titan
ImmuCell Corporation Files Form 8-K with SEC Detailing Corporate Information and Press Release March 2026 - Minichart
ImmuCell appoints Kathy Turner to board of directors - Investing.com
ImmuCell (NASDAQ: ICCC) names Kathy Turner to Board as Rosgen retires - Stock Titan
Former Elanco director joins ImmuCell board in calf-health push - Stock Titan
ImmuCell Corp (ICCC) Q4 2025 Earnings Call Highlights: Navigating Growth Amidst Challenges By GuruFocus - Investing.com Canada
ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve - Yahoo Finance
ImmuCell Corporation (NASDAQ:ICCC) Q4 2025 Earnings Call Transcript - Insider Monkey
ImmuCell Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: ImmuCell’s Q4 2025 shows growth despite challenges - Investing.com
ImmuCell Corporation Q4 2025 Earnings Call Summary - Yahoo Finance
ICCC Earnings History & Surprises | EPS & Revenue Results | IMMUCELL CORP (NASDAQ:ICCC) - ChartMill
ImmuCell Corporation Reports Improved Financial Results for 2025 with Increased Net Operating Income and Revenue Growth - Quiver Quantitative
ImmuCell (Nasdaq: ICCC) lifts 2025 EBITDA and narrows annual net loss - Stock Titan
ImmuCell Corporation (NASDAQ:ICCC) Sees Significant Growth in Short Interest - MarketBeat
ImmuCell Corporation to Announce Unaudited Financial Results for Q4 and Year-End 2025 on March 4, 2026 - Quiver Quantitative
ImmuCell (NASDAQ:ICCC) Stock Price Crosses Above 200-Day Moving Average – What’s Next? - Defense World
Does ImmuCell Corporation have a sustainable dividendJuly 2025 WrapUp & Stepwise Entry/Exit Trade Alerts - mfd.ru
Why retail investors pile into ImmuCell Corporation stockJuly 2025 Big Picture & Low Risk Investment Opportunities - mfd.ru
Will ImmuCell Corporation benefit from AI trendsBear Alert & Weekly Momentum Stock Picks - mfd.ru
ImmuCell directors to step down at 2026 annual meeting, board changes expected By Investing.com - Investing.com South Africa
ImmuCell directors to step down at 2026 annual meeting, board changes expected - Investing.com
Two ImmuCell (ICCC) directors to step down after 2026 shareholder meeting - Stock Titan
ImmuCell announces new executive employment agreements and option grants By Investing.com - Investing.com South Africa
ImmuCell announces new executive employment agreements and option grants - Investing.com
Immucell Corp Stock (ICCC) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):